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S U M M A R Y
Background: The efﬁcacy of probiotics for the prevention of Clostridium difﬁcile infection (CDI) is highly
controversial, particularly with regard to the prevention of recurrent CDI. We hypothesize that primary
prevention of CDI among patients receiving antibiotics might be a more achievable goal for probiotics
than prevention in patients with previous CDI where the host ﬂora is markedly altered.
Methods: We conducted a literature search for randomized, placebo-controlled efﬁcacy studies of
probiotic use among adults receiving antibiotics, in which CDI was one of the outcomes measured. In
addition, we conducted meta-analyses of probiotics that were included in more than one randomized
trial.
Results: Eleven studies were identiﬁed; most were seriously underpowered to determine the efﬁcacy of
probiotics in the prevention of CDI. Two showed signiﬁcantly lower rates of CDI among the probiotic
recipients. A meta-analysis of three studies that used the probiotic combination Lactobacillus acidophilus
CL1285 and Lactobacillus casei LBC80R and a combined analysis of those studies with four studies that
used Saccharomyces boulardii, showed lower CDI rates in recipients of probiotics compared with
recipients of placebo (risk ratio = 0.39; 95% conﬁdence interval 0.19–0.79).
Conclusions: While potential ﬂaws in study design were identiﬁed, a review of the available literature
suggests that the primary prevention of CDI with speciﬁc probiotic agents may be achievable. Additional
studies of sufﬁcient size and with rigorous design are needed to conﬁrm these ﬁndings.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
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Antibiotics are the major risk factor for a primary episode of
Clostridium difﬁcile infection (CDI), as well as an important factor
for recurrent CDI. The risk associated with antibiotics primarily
relates to disruption of the protective host colonic microbiota, but
may also involve selection for C. difﬁcile strains resistant to the
inciting agent.1 Adjunctive therapy with probiotics has been used
widely for patients with CDI, with and without the guidance of
physicians. The goal of probiotic therapy is to mitigate the effects of
microbiota disruption, and different mechanisms have been* Corresponding author.
E-mail address: stuart.johnson2@va.gov (S. Johnson).
1201-9712/$36.00 – see front matter . Published by Elsevier Ltd on behalf of Internatio
http://dx.doi.org/10.1016/j.ijid.2012.06.005proposed whereby speciﬁc probiotics affect the microbiota and
interfere with C. difﬁcile.2
Most studies of CDI prevention have focused on secondary
prevention (i.e., prevention of CDI recurrence), mainly because the
risk for CDI is sufﬁciently high in patients with a recent CDI episode
that the effect of intervention is easier to demonstrate; 20–30%
after the ﬁrst episode and 50% after the second episode.3 The rate
of primary episode CDI among antibiotic recipients varies with
different antibiotics and populations studied, but is much lower
than the rate of recurrent CDI and usually is much less than 10%.4
Therefore, a larger study population is needed to demonstrate
efﬁcacy in primary CDI prevention.
The efﬁcacy of probiotics in the prevention of CDI has been
hotly debated,5,6 but many studies and meta-analyses have
combined primary and secondary CDI prevention data, whichnal Society for Infectious Diseases.
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probiotic interventions between these populations. It is our
hypothesis that probiotics may be more effective in primary CDI
prevention (those patients at risk for CDI) than in secondary
prevention of recurrent CDI in patients with an established C.
difﬁcile infection. This study includes a general overview of
probiotics studied for CDI prevention and a systematic analysis
of randomized studies of primary prevention of CDI with
probiotics.
1.1. Probiotics studied for the prevention of CDI
1.1.1. Speciﬁc probiotic organisms
Several bacterial and fungal species have been studied or are
under study to determine their efﬁcacy against CDI either as single
probiotic agents or in combination with other agents (Table 1).
These agents include Saccharomyces boulardii and several Lactoba-
cillus, Clostridium, Streptococcus, and Biﬁdobacterium species. S.
boulardii and Lactobacillus rhamnosus GG are two of the best
characterized probiotic organisms for use in CDI.
S. boulardii is a yeast that is a subspecies of Saccharomyces
cerevisiae, which was initially isolated from lychee and mango-
steen fruits. It secretes a 54-kDa protease, in vivo.7 In vitro, this
protease has been shown to both degrade toxins A and B secreted
from C. difﬁcile and inhibit their binding to receptors along the
brush border, leading to a reduction in the enterotoxic and
cytotoxic effects of C. difﬁcile.7 L. rhamnosus GG is a naturally-
occurring strain that was isolated from human feces and was
selected for its potential probiotic properties: acid- and bile-
stability, great avidity for human intestinal mucosal cells,
reduction of intestinal permeability defects, and enhancement
of intestinal immunity.2
Bio-K+ CL1285 is a probiotic combination (Lactobacillus
acidophilus CL1285 and Lactobacillus casei LBC80R) that has been
studied in three recent clinical trials of antibiotic-associated
diarrhea (AAD) and CDI,8–10 and has been shown to survive acid,
pepsin, and bile salt in vitro.11
1.1.2. Probiotic formulations and correlates of efﬁcacy
Probiotics, in general, vary widely in their manufacturing
processes, and many commercial products lack regulated quality
control programs resulting in contamination with other organisms,
as well as bacteria counts that are different from the label on the
product.6 Stability of the product and viability of the organism at
the time of ingestion are critical factors for efﬁcacy and are not
always guaranteed by the manufacturer. In contrast, S. boulardii
and Bio-K+ CL1285 have undergone rigorous testing to ensure
organism viability and concentration.5 Bio-K+ CL1285 has been
formulated as fermented milk8,9 and freeze-dried bacteria placed
in an enteric coated capsule.10 Both products contain 50 billion liveTable 1
Probiotics studied for prevention of Clostridium difﬁcile infection
Single agent formulations
Saccharomyces boulardii
Lactobacillus rhamnosus GG
Lactobacillus plantarum 299v
Clostridium butyricum M588
Clostridium difﬁcile VP20621 (non-toxigenic C. difﬁcile strain)
Combination agent formulations
Lactobacillus casei, Lactobacillus acidophilus (Bio-K + CL1285)
Lactobacillus casei, Lactobacillus bulgaricus, Streptococcus thermophilus
(Actimel)
Lactobacillus acidophilus, Biﬁdobacterium biﬁdum (Florajen3)
Lactobacillus acidophilus, Lactobacillus bulgaricus delbrueckii subsp. bulgaricus,
Lactobacillus bulgaricus casei, Lactobacillus bulgaricus plantarum, Biﬁdobacterium
longum, Biﬁdobacterium infantis, Biﬁdobacterium breve, Streptococcus salivarius
subsp. thermophilus (VSL#3)and active L. acidophilus CL1285 and L. casei LBC80R at the date of
consumption (140 days for fermented milk and 2 years for capsules
if kept refrigerated). Validation of the probiotic concentration in
samples of Florastor (S. boulardii) and Bio-K+ obtained from the
store was recently reported.12 Susceptibility of the probiotic
organisms to particular antibiotics is also theoretically important,
as these products are usually recommended to be given during or
shortly after antibiotic administration. However data on suscepti-
bility or relative susceptibility of probiotics to the multiple
different antibiotics that a patient may receive are scarce.
Another factor that appears to be critical for probiotic efﬁcacy is
the number of organisms given. In one review of 25 randomized
trials, administration of probiotics at concentrations of 1010
colony forming units (CFU)/day was associated with efﬁcacy.5 Both
S. boulardii and Lactobacillus GG (LGG) can be detected in stool
samples of patients ingesting these probiotics. S. boulardii is
cleared within 3 days after stopping dosing,13 but LGG may be
detected for up to 7 days in 30% of subjects.2 The fecal
concentration of S. boulardii also predicts recurrence of CDI. When
given for 28 days after standard antibiotic treatment for CDI,
patients with low S. boulardii concentrations (<104/g stool)
experienced recurrences more often than those with levels
>104/g.13
1.2. Animal models of CDI prevention
Animal models provide a useful method to evaluate the
effectiveness of probiotics for the prevention of CDI. In hamsters
pre-treated with antibiotics, the administration of cecal homo-
genates containing the complete indigenous microbiota were
highly effective in providing protection from the development of
cecitis after challenge with toxin-producing C. difﬁcile.14 These data
are consistent with the subsequent demonstration that stool
transplantation is effective in preventing recurrences of CDI in
patients.15 Speciﬁc non-toxigenic strains of C. difﬁcile have been
shown to effectively colonize clindamycin-treated hamsters and
offer at least 95% protection against subsequent lethal challenge
with virulent, toxin-producing strains.16 In hamsters treated for
CDI with vancomycin, S. boulardii treatment resulted in a modest
reduction in C. difﬁcile counts and a more dramatic decrease in
toxin levels (3% of S. boulardii-treated hamsters had detectable
toxin B versus 51% of controls).17 In mice, S. boulardii did not reduce
the concentration of C. difﬁcile, but markedly reduced levels of
toxins A and B and prevented damage to the intestinal mucosa.18
Two mouse model studies have suggested a potential role for
lactobacilli in reducing the severity of CDI,19,20 but the conclusions
that can be drawn from these small-scale studies are limited. There
is a need for additional animal model studies to evaluate the
effectiveness of various probiotic preparations for the prevention
of CDI.
1.3. Potential risks of probiotics
The primary concern for adverse outcomes associated with
probiotic use is the acquisition of probiotic-related infections and
their associated complications. In the USA, probiotics have been
regulated as dietary supplements by the Food and Drug
Administration (FDA);21 as a consequence, probiotics have never
been subjected to the comprehensive safety evaluations that
pharmaceuticals receive, and robust probiotic safety data are
scarce. However, the FDA established a requirement for reporting
probiotic adverse events in 2006.21
Population-based studies have found no increase in the
incidence of Lactobacillus bacteremia after the introduction and
widespread use of Lactobacillus paracasei, L. acidophilus, and L.
rhamnosus probiotics in dairy products either in Finland or
Table 2
Randomized controlled trials of probiotics for primary CDI prevention in patients receiving antibiotics
Probiotic
(daily dose, CFU)
Population
(n, number
evaluated)
Treatment duration
(follow-up duration)
CDI rate p-Value Power to detect
p  0.05
Comments Reference
Placebo Probiotic
Saccharomyces boulardii
21010
Adult inpatients
(180)
Duration of
antibiotics +14 days (no f/up)
5/64 (7.8%) 3/116 (2.6%) NS 26.5% 1 USA hospital Surawicz et al., 198933
S. boulardii
31010
Adult inpatients
(193)
Duration of
antibiotics +3 days (7 weeks f/up)
4/96 (4.2%) 3/97 (3.1%) NS 2.6% 4 USA hospitals,
patients on beta-
lactam antibiotics
McFarland et al., 199534
S. boulardii
4.5109
Elderly patientsa
(69)
Duration of antibiotics (no f/up) 3/36 (8.3%) 5/33 (15.2%) NS 7.2% 1 UK hospital Lewis et al., 199835
S. boulardii
11010
Adult inpatients
(151)
Duration of antibiotics
(4 weeks f/up)
2/78 (2.6%) 0/73 (0%) NS 9.1% 1 Turkish hospital Can et al., 200636
Lactobacillus acidophilus,
Biﬁdobacterium biﬁdum
21010 CFU
Elderly adultsa
(138)
20 days (no f/up) 5/69 (7.2%) 2/69 (2.9%) NS 11.5% 1 UK hospital Plummer et al., 200439
Lactobacillus rhamnosus GG
21010 CFU
Adult inpatients
(267)
14 days (7 days f/up) 3/134 (2.2%) 2/133 (1.5%) NS 2.7% 1 USA hospital Thomas et al., 200140
Lactobacillus casei,
Lactobacillus bulgaricus,
Streptococcus thermophilus
4.21010 CFU
Adults (112) Duration of antibiotics +7 days
(f/up 4 weeks after discharge)
9/53 (17.0%) 0/56 (0%) p=0.001 80.8% 3 UK hospitals,
patients on high
risk antibiotics
excludedb (Actimel)
Hickson et al., 200741
L. acidophilus, L. bulgaricus,
B. biﬁdum, S. thermophilus
1.5109 CFU each or total
of 6109/day
Adult inpatients
(42)
3 weeks (no f/up) 1/21 (4.8%) 3/21 (14.3%) NS 7.2% 1 Israeli hospital
(BioGuard)
Stein et al., 200742
L. acidophilus CL1285,
L. casei LBC80R
51010 CFU
Adult inpatients
(89)
Duration of antibiotics
(additional 21 days f/up)
7/45 (15.6%) 1/44 (2.3%) NS (p=0.06) 44.2% 1 Canadian hospital,
9-month study (Bio-K+,
fermented milk)
Beausoleil et al., 20078
L. acidophilus CL1285,
L. casei LBC80R
51010 CFU
Adults (437) Duration of antibiotics + 5 days
(additional 21 days f/up)
4/221 (1.8%) 1/216 (0.5%) NS 12.5% 8 Canadian hospitals,
patients on antibiotics
for 3–14 days (Bio-K+,
fermented milk)
Psaradellis et al., 20109
L. acidophilus CL1285,
L. casei LBC80R
51010 CFU or 101010
CFU
Adult inpatients
(255)
Duration of antibiotics + 5 days
(additional 21 days f/up)
20/84 (23.8%) Low
dose: 8/85
(9.4%)
High dose:
1/86 (1.2%)
Low
dose: p=0.03
High
dose: p=0.002
Low dose
64.0%
High
dose 99.2%
1 Chinese hospital,
3-month study
(Bio-K+, capsules)
Gao et al., 201010
CDI, Clostridium difﬁcile infection; CFU, colony forming units; NS, not signiﬁcant.
a Elderly was deﬁned as age >65 years,35 or as participants enrolled at a hospital for the elderly.39
b High risk antibiotics were deﬁned as clindamycin, cephalosporins, and aminopenicillins.41
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infections with both S. boulardii- and Lactobacillus species-based
probiotic preparations have occurred,24–29 primarily in immuno-
compromised patients, such as those with severe neutropenia, HIV,
and malignancy.24–26
To date, the most rigorous probiotic safety data have been
generated for two Lactobacillus combination preparations. A study
investigating 1176 inpatients who were administered an L.
acidophilus and Lactobacillus bulgaricas combination estimated a
maximal probiotic-related bacteremia rate of 0.2%.30 The patient
population was well characterized and 47% had moderate or severe
immunosuppression, 33% had impaired intestinal integrity, 20%
had abnormal heart valves, and 54% were prescribed concurrent
proton pump inhibitors. Only two suspected L. acidophilus
bacteremias were identiﬁed, and neither infection could be
deﬁnitively determined as probiotic-related as patient isolates
were unavailable for molecular typing and comparison to probiotic
strains.
Similarly, an L. acidophilus CL1285 and L. casei LBC80R
combination has been administered to 781 adult inpatients in
three trials,8–10 without a single probiotic infection. However these
trials speciﬁcally excluded immunosuppressed patients. More
compelling is the report of the administration of this combination
product to 30 000 adult inpatients receiving antibiotics at a single
hospital, without any patient exclusions and without a single
recognized episode of probiotic-related bacteremia.31
2. Methods
2.1. Analysis of randomized primary CDI prevention studies—
systematic review search strategy
PubMed, Medline, and Google Scholar were searched for the
period 1976 to 2010 for articles unrestricted by language. Three
on-line clinical trial registers were searched: Cochrane Central
Register of Controlled Trials (http://www.cochrane.org), metaR-
egister of Controlled Trials (www.controlled-trials.com/mrct), and
the National Institutes of Health (www.clinicaltrials.gov). Second-
ary and hand searches of reference lists, other studies cross-
indexed by authors, reviews, commentaries, books, and meeting
abstracts were also performed. Search terms included: Clostridium
difﬁcile disease, probiotics, Lactobacillus, BioK+, LGG, Saccharomy-
ces boulardii, yeast, diarrhea, randomized controlled trials, place-
bo-controlled, phase 3, and associated author names. Search
strategies were broad-based initially, then narrowed to the disease
of interest to increase the search network.32
The main objective of this literature search was to determine
the overall efﬁcacy of probiotics for the primary prevention of CDI
by comparing a common outcome in treated patients with a
control group. Inclusion criteria included: randomized, controlled,
blinded efﬁcacy trials of primary prevention in adult patients
published as full articles and where CDI was one of the outcomes
measured.
2.2. Meta-analysis of probiotic primary CDI prevention studies
We performed a meta-analysis to explore the between-trial
heterogeneity for speciﬁc probiotic formulations and to provide
more precise estimates of formula-speciﬁc effect sizes. As such,
and to minimize the noise from formulations that only had a single
randomized controlled trial, we conducted a meta-analysis on
trials involving probiotic agents that were studied in more than
one trial. Two probiotic preparations have been studied in more
than one randomized trial: L. acidophilus + L. casei (Bio-K+
International, Laval, QC; CL1285) (n = 3) and S. boulardii (n = 4).
We analyzed data from the published randomized controlled trialsin which patients receiving antibiotics were randomized to either
L. acidophilus + L. casei or placebo,8–10 and S. boulardii or placebo,33–
36 and in which AAD and CDI were the primary and secondary
outcomes, respectively. We analyzed only the CDI outcome. All the
L. acidophilus + L. casei studies used a fermented milk or capsule
formulation of 5  1010 CFU L. acidophilus CL1285 and L. casei
LBC80R. One study had an additional ‘high dose’ arm in which two
doses were given (high dose 10  1010 CFU);10 for this study, we
aggregated results for the high- and low-dose formulations and
compared them to placebo. The S. boulardii studies used capsule
formulations containing between 4.5  109 and 3  1010 CFU of S.
boulardii. We expressed the efﬁcacy of L. acidophilus + L. casei or S.
boulardii on the incidence of CDI as relative risks (values <1
indicate a beneﬁt) with 95% conﬁdence intervals (95% CI). We
present the results for each probiotic preparation separately and
the overall effect. We used the metan command for Stata,37 using
Stata version 10.1 software (Stata Inc., College Station, TX, USA).
We speciﬁed a random effects analysis. We report the I2 result as a
measure of inter-study heterogeneity.38
3. Results
3.1. Description of randomized primary CDI prevention trials
We identiﬁed 11 published studies8–10,33–36,39–42 among adults
receiving antibiotics who were randomized to a probiotic or
probiotic combinations versus placebo and in which CDI was one of
the outcomes measured (Table 2). The primary outcome measure
in the majority of these studies was AAD, and CDI was a secondary
outcome. Four of these studies involved S. boulardii and seven
involved Lactobacillus sp alone (n = 1) or in combination with other
Lactobacillus sp or other organisms (n = 6). The population studied
was hospitalized patients in almost all cases, and the studies were
conducted in the USA (three studies), UK (three studies), Canada
(two studies), and Israel, Turkey, and China (one study each). The
rate of CDI among the placebo groups was less than 10% for eight of
the studies. Most studies were not powered sufﬁciently to detect a
signiﬁcant difference; only two studies had >60% power to detect a
signiﬁcant difference of p < 0.05 (Table 2). There were more CDI
cases in the placebo group than in the probiotic group in nine of the
11 studies, but the difference was only signiﬁcant in two
studies.10,41 The rates of CDI in the placebo recipients in these
two studies (17.0% and 23.8%) were the highest among all the
studies, and the study with the next highest CDI rate in placebo
recipients (15.6%) showed a strong trend towards probiotic
effectiveness (p = 0.06).8 This latter study was conducted between
September 2003 and May 2004 in a Montreal hospital during a
multi-hospital CDI outbreak in the Montreal area;43 this timing
may explain the high rate of CDI among placebo recipients. It is
unknown if there was an outbreak at the time of the studies in the
UK and Chinese hospitals at which the placebo CDI rates were the
highest.10,41 The epidemiology of CDI in China, in particular, is
unclear, and the Chinese study was conducted at a single Shanghai
hospital where 255 patients were enrolled over a 3-month period
in 2009.10
There are caveats to keep in mind in the comparison of these
reports, as there were several differences in study design, including
population studied, probiotic treatment duration, length of follow-
up (Table 2), exclusion criteria, and non-systematic testing of
patients with AAD for C. difﬁcile. The more recent studies explicitly
mentioned prior CDI as an exclusion criterion8–10,40 or screened
patient stools at baseline for C. difﬁcile.39,41,42 The S. boulardii
studies, however, did not speciﬁcally mention CDI as an exclusion
criterion.33–36 Although patients with prior CDI could potentially
have been enrolled in these studies, all of the studies excluded
patients with recent diarrhea episodes and two excluded patients
S. Johnson et al. / International Journal of Infectious Diseases 16 (2012) e786–e792e790receiving treatment agents for CDI (e.g., oral vancomycin,
teicoplanin, or metronidazole).33,36
3.2. Meta-analysis of multiple trials employing the same probiotic
combinations
The three most recently reported studies used the same
probiotic, a formulation of 5  1010 CFU L. acidophilus CL1285
and L. casei LBC80R (Bio-K+ International, Laval, QC, Canada), and
were conducted using similar methods (Table 2). A meta-analysis
of these studies showed an overall effect of lower CDI rates among
those taking the probiotic compared with those taking the placebo
(risk ratio 0.21, 95% CI 0.11–0.42; p < 0.001) (Figure 1). Despite
variability in study design and prevalence of CDI, there was little
heterogeneity in the effect estimate (I2 = 0%; p = 0.92). A meta-
analysis of the four studies that used S. boulardii showed a trend
towards lower CDI rates in the probiotic group, but this result was
not signiﬁcant (risk ratio 0.70, 95% CI 0.29–1.69) and there was
more heterogeneity (I2 = 17.2%; p = 0.30). A meta-analysis of all
seven studies with these probiotic preparations showed a
combined overall effect of lower CDI rates among antibiotic
recipients randomized to probiotics than those randomized to
placebo (risk ratio 0.39, 95% CI 0.19–0.79; heterogeneity of the
effect estimate: I2 = 33.9%; p = 0.17).
3.3. Additional trials of primary CDI prevention
Three primary prophylaxis studies that did not meet our
inclusion criteria, but were noteworthy nonetheless, included one
randomized study that measured C. difﬁcile colonization as the
outcome and two non-randomized time-series analyses that
measured CDI rates.
The ﬁrst study randomized critically ill patients taking antibiotics
in an intensive care unit setting to Lactobacillus plantarum 299 v or
placebo and sampled stools for C. difﬁcile colonization twice a week.
Four of 21 placebo recipients versus none of 22 patients receiving L.
plantarum 299 v became colonized (p = 0.0485).44Combined overall effect
L. casei & L. acidophilus
Surawicz
Lewis
Beausoleil
McFarland
Can
Overall effect, subgroup
Gao
Psaradellis
S. boulardii
1.01
Overall effect, subgroup
Favors probiotic                     Favo
Figure 1. Meta-analysis of three randomized trials for primary prevention of CDI using Lac
four trials using Saccharomyces boulardii among antibiotic recipients. The combined ove
conﬁdence interval (CI) of CDI for patients taking the probiotic compared with patients ta
estimate of the overall RR.The next study encouraged physicians to write orders for a
probiotic combination (L. acidophilus and Biﬁdobacterium biﬁdum)
three times daily for inpatients prescribed antibiotics.45 They
documented that 60% of eligible patients received the probiotic
and also reported a lower CDI rate compared with historical rates
in their hospital (10.28 cases/1000 discharges for the 2 years prior
to the intervention and 3.27 cases/1000 during the year-long
intervention).
The third study reported an intervention in a community
hospital in Quebec that was implemented during the multi-
hospital CDI outbreak in which the epidemic C. difﬁcile strain BI/
NAP1/027 predominated.31 Beginning February 2004, Bio-K+
CL1285 was distributed automatically by the pharmacy depart-
ment to every patient started on antibiotics and was continued for
a duration of 30 days. In the ﬁrst 18 months of the intervention, a
73% reduction in nosocomial CDI cases (from 18.4 to 5.0 cases/
1000 admissions, p = 0.003) and a 94% reduction in severe CDI
cases (from 5.1 to 0.3 cases/1000 admissions, p = 0.003) was
noted. As of November 2010, over 30 000 patients have received
the probiotic in this hospital and no cases of Lactobacillus
septicemia have been recognized (personal communication, Dr
P.J. Maziade).
4. Discussion
Results of CDI prevention studies using probiotics have not
been convincing, particularly in secondary CDI prevention for
patients with a recent CDI episode,6 and the recently published
Society for Healthcare Epidemiology of America (SHEA)/ Infec-
tious Diseases Society of America (IDSA) guidelines found
insufﬁcient evidence to recommend probiotics for this indica-
tion.46 These concerns about the lack of probiotic efﬁcacy in
secondary prevention may have inﬂuenced the criticism of
probiotic trials for primary prevention. A recently reported
randomized, double-blind, placebo-controlled study of a probi-
otic Lactobacillus/Streptococcus thermophilus preparation dem-
onstrated a 22% reduction in AAD and a 17% reduction in CDI0.26 (0.03, 2.27)
Event rate
3/116
5/33
1/44
0/73
9/171
45/624
14/274
5/64
3/36
7/45
4/96
2/78
31/350
20/84
Control
4/221
0.39 (0.19, 0.79)
0.70 (0.29, 1.69)
0.33 (0.08, 1.34)
1.82 (0.47, 7.02)
0.15 (0.02, 1.14)
0.74 (0.17, 3.23)
0.21 (0.01, 4.37)
0.21 (0.11, 0.42)
0.22 (0.11, 0.46)
RR (95% CI)
22/750
11/319
3/97
11/431
Treatment
1/216
5
rs placebo
tobacillus acidophilus CL1285 and Lactobacillus casei LBC80R (Bio-K+ CL1285) and the
rall effect for these seven trials is shown on the bottom. Relative risk (RR) and 95%
king placebo is indicated for each study. The vertical dashed line represents the point
S. Johnson et al. / International Journal of Infectious Diseases 16 (2012) e786–e792 e791among hospitalized patients taking antibiotics.41 This study was
widely criticized for questionable choice and blinding of the
placebo drink and the numerous exclusions in the protocol,
including high risk antibiotics, making it difﬁcult to understand
how these results, if repeatable, would be generalizable.47,48 The
results, however, were subsequently repeated in a randomized
study using another Lactobacillus preparation, L. casei and L.
acidophilus (Bio-K+ CL1285), that did not exclude high risk
antibiotics.10 While there are questions about the design and
execution of this study as well, there are reasons to hypothesize
that probiotics might be more efﬁcacious in primary CDI
prevention than in secondary prevention. We hypothesize
that the efﬁcacy of probiotics for the prevention of CDI relates
to the extent of disruption of the protective host colonic
microbiota.
Appreciation of the extent and diversity of the human colonic
microbiota has been enhanced with the development of culture-
independent techniques based on ampliﬁcation of 16s rRNA.49
Antibiotics have a profound effect on the richness, evenness, and
diversity of the microbiota, even in the absence of overt
gastrointestinal symptoms.50 Chang et al. used similar techni-
ques to study the microbiota of patients with initial CDI
episodes and recurrent CDI episodes compared to controls
without CDI infection.51 The striking ﬁnding in that study was
the marked redistribution of major bacterial phyla and much
lower diversity of the biota among the patients with recurrent
CDI. In contrast, the microbiota in patients with an initial CDI
episode was more similar to that of the controls than that of the
recurrent CDI patients. It is possible that the opportunity for a
probiotic effect is greatest at the time of initial exposure to C.
difﬁcile following antibiotic disruption of the ﬂora but before the
more pervasive disruption following established infection with
C. difﬁcile.
Even though the majority of the randomized probiotic studies
of primary prevention for CDI did not show statistically signiﬁcant
differences and were seriously underpowered for this outcome
evaluation, the trend was towards protection in nine of the 11
studies. Our meta-analysis provided the opportunity to better
understand these trends for the two best-studied probiotic
formulations (L. acidophilus + L. casei and S. boulardii). Our ﬁndings
indicate a consistent and signiﬁcant effect for the L. acidophilus + L.
casei formulation and a trend towards a beneﬁcial effect for S.
boulardii preparations; the combined overall effect showed
signiﬁcant protection from CDI (Figure 1).
The recent reports of primary prophylaxis attempts using the
Lactobacillus preparation Bio-K+ CL12858–10 are particularly
encouraging. The 9-month study conducted in one Montreal
area hospital during the 2003–2004 BI/NAP1/027 CDI epidemic
came close to showing effectiveness of this product for CDI
prevention.8 Furthermore, the analysis of the three L. acidophilus
+ L. casei studies and the overall combined meta-analysis of the
L. acidophilus + L. casei and S. boulardii studies showed signiﬁcant
protection against CDI among antibiotic recipients who took
probiotics during their time at risk. While the extraordinary rate
of CDI among the placebo recipients in the two studies showing
efﬁcacy10,41 is still incompletely explained, the possibility of
primary CDI prevention using speciﬁc probiotics is intriguing
and worthy of further study.
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